Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve 1. Unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has informed BSE that its Board of Directors will meet on 13 November 2025 at the registered office in Hyderabad. The key agenda items are approval of the unaudited financial results for the quarter ended 30 September 2025 and the Limited Review Report from auditors for the same period. The board may also take up any other business with the Chair's permission. No financial figures or outcomes have been disclosed yet — this is a routine pre-results intimation filed under SEBI LODR Regulation 29(1)(a).
No immediate impact on shareholders or stock price — this is a standard procedural filing. Investors should watch for the actual Q2 FY26 results on or after 13 November for any meaningful updates on revenue, profitability, or margins.